Activity of intravenous menogaril in patients with previously untreated metastatic breast cancer. A National Cancer Institute of Canada Clinical Trials Group study.

Abstract

We have carried out a phase II study of intravenous menogaril given every four weeks in a group of patients with breast cancer who had received no prior chemotherapy for metastatic disease. Myelosuppression, nausea and vomiting and local reactions were seen frequently. Six partial responses (median duration 154 days) were seen in 24 eligible patients. We conclude menogaril is active in breast cancer and recommend that because it can be delivered in high doses orally, future trials in this disease should focus on intense oral schedule.

• Authors: E A Eisenhauer, K I Pritchard, D J Perrault, S Verma, J L Pater
• Journal: Investigational new drugs (Invest New Drugs) Vol. 8 Issue 3 Pg. 283-7 (Aug 1990) ISSN: 0167-6997 [Print] United States
• PMID: 2148741 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antineoplastic Agents
• Menogaril
• Nogalamycin

Topics

• Adult
• Aged
• Antineoplastic Agents (pharmacology, therapeutic use, toxicity)
• Breast Neoplasms (drug therapy, secondary)
• Drug Administration Schedule
• Drug Evaluation
• Female
• Heart (drug effects)
• Humans
• Infusions, Intravenous
• Menogaril
• Middle Aged
• Nogalamycin (analogs & derivatives, pharmacology, therapeutic use, toxicity)
• Stroke Volume (drug effects)
• Ventricular Function, Left (drug effects)